Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease: a Pilot Study

  • STATUS
    Recruiting
  • End date
    May 31, 2023
  • participants needed
    25
  • sponsor
    McGill University Health Centre/Research Institute of the McGill University Health Centre
Updated on 1 May 2022
tacrolimus
cyclosporine
immunosuppressive
prednisone
respiratory symptom
nintedanib
immunosuppression
fibrosis
bronchiectasis
azathioprine
rheumatic diseases
igiv
dermatomyositis
polymyositis
myopathy
forced vital capacity
interstitial lung disease
ciclosporin

Summary

There is likely a role for using anti-fibrotic medications in patients with myositis-associated interstitial lung disease (MA-ILD) to slow down disease progression, especially in patients who have fibrotic and progressive disease. These patients however are currently being excluded from clinical trials of anti-fibrotic agents in progressive ILD because of the concomitant use of immunosuppression. The benefit of anti-fibrotic agents is being assessed in other rheumatic diseases and should be assessed in MA-ILD as well. They are a unique group of patients with a heterogeneous disease, and are much more frequently on concomitant immune-modulating therapy. As such, they should be studied on their own in separate clinical trials, and the use of nintedanib should be studied as an addition to standard of care immunosuppression.

The objective of this study is to assess safety and tolerability of nintedanib in patients with MA-ILD.

Details
Condition Interstitial Lung Disease, Myopathy, Inflammatory
Treatment Nintedanib 150 milligrams [Ofev]
Clinical Study IdentifierNCT05335278
SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre
Last Modified on1 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

\. 18 years and older 2. Diagnosis of autoimmune myopathy (dermatomyositis, polymyositis, overlap myositis or anti-synthetase syndrome) as diagnosed by a rheumatologist. 3. Interstitial lung disease confirmed by high resolution CT scan (Extent of disease 10% or more on CT done within 12 months of enrolment) with evidence of fibrosis, defined as reticular abnormality with traction bronchiectasis with or without honeycombing. 4. Evidence of progressive disease within 24 months of screening visit
Clinically significant decline in Forced Vital Capacity (FVC) % pred based on a relative decline of >=10%
Marginal decline in FVC % pred based on a relative decline of .>=5-<10% combined with worsening of respiratory symptoms
Marginal decline in FVC % pred based on a relative decline of >=5-<10% combined with increasing extent of fibrotic changes on chest imaging
Worsening of respiratory symptoms such as cough or shortness of breath as well as increasing extent of fibrotic changes on chest imaging as per radiologist or pulmonologist who read the scan 5. Current and ongoing treatment with immunosuppressive medications, on a stable medication regimen and dosage for at least 6 weeks (considered standard of care medical therapy) Concomitant medications allowed are
mycophenolate
azathioprine
tacrolimus
cyclosporine
rituximab (injection within the last year)
prednisone low dose =<20 mg daily
Intravenous immunoglobulins

Exclusion Criteria

Contraindication to treatment with nintedanib (based on Canadian labeling)
The female patient is pregnant, plans to become pregnant during the course of the study, or is breastfeeding
The male patient plans to father a child during the course of the study
Hypersensitivity to nintedanib, peanut or soy
Elevated liver enzymes greater than 1.5 times the upper limit of normal
Creatinine clearance <30 mL/min
Patient with risks factors of aneurysm or artery dissection, such as known history of aneurysm or uncontrolled hypertension
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note